National Mutual Insurance Federation of Agricultural Cooperatives grew its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 279.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,000 shares of the company’s stock after purchasing an additional 67,000 shares during the period. Johnson & Johnson comprises about 0.2% of National Mutual Insurance Federation of Agricultural Cooperatives’ portfolio, making the stock its 29th largest position. National Mutual Insurance Federation of Agricultural Cooperatives’ holdings in Johnson & Johnson were worth $14,866,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Cim LLC lifted its holdings in Johnson & Johnson by 6.0% during the third quarter. Cim LLC now owns 9,807 shares of the company’s stock worth $1,697,000 after acquiring an additional 556 shares during the period. Aries Wealth Management raised its stake in shares of Johnson & Johnson by 0.9% during the 3rd quarter. Aries Wealth Management now owns 30,985 shares of the company’s stock worth $5,390,000 after purchasing an additional 273 shares during the period. Hardman Johnston Global Advisors LLC boosted its holdings in shares of Johnson & Johnson by 0.9% in the 3rd quarter. Hardman Johnston Global Advisors LLC now owns 156,567 shares of the company’s stock worth $25,577,000 after buying an additional 1,335 shares during the last quarter. Rice Partnership LLC increased its holdings in Johnson & Johnson by 12.3% during the third quarter. Rice Partnership LLC now owns 53,655 shares of the company’s stock worth $8,765,000 after buying an additional 5,868 shares during the last quarter. Finally, Aptus Capital Advisors LLC boosted its stake in Johnson & Johnson by 7.2% in the third quarter. Aptus Capital Advisors LLC now owns 77,500 shares of the company’s stock valued at $12,661,000 after acquiring an additional 5,177 shares during the last quarter. 67.94% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
JNJ has been the topic of several research analyst reports. Bank of America dropped their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research note on Friday, October 14th. Morgan Stanley cut their price target on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 6th. Sanford C. Bernstein lowered their price objective on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Citigroup increased their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Finally, StockNews.com began coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $181.75.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.23 by $0.12. The company had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. Johnson & Johnson’s revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.13 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post 10.04 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 annualized dividend and a yield of 2.69%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the sale, the chief financial officer now owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Jennifer L. Taubert sold 76,923 shares of the company’s stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold a total of 233,611 shares of company stock valued at $40,960,735 over the last 90 days. 0.35% of the stock is owned by insiders.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.